Sysmex Perspective Series

With changing healthcare dynamics such as the increasing average age of patients, a less healthy society, increased demand for tests and decreased funding, many laboratories are feeling the impact. One area where this impact is highlighted relates to the use of pathology to control chronic disease. A topic covered incredibly well by Dr Beverley Rowbotham, Director of Haematology at Sullivan Nicolaides Pathology (Brisbane) at the National Pathology Forum Sydney in 2013.

Deborah Steele, Product Manager for the Health IT product suite at Sysmex, outlines the key points from this presentation.

The burden of chronic disease is increasing rapidly in our populations. This in turn drives an increase in pathology testing. Are more tests being ordered because there is not enough information about how test results should best be interpreted? Can clinicians pick a true change in test results, and therefore clinically significant patterns? The answer to these questions indicated information available at the point of test ordering is insufficient and there are gaps in the interpretation of patient lab reports.

Using HBA1C as an example, on average six monthly testing is unnecessary (Aronsen et al, NHS Diabetes). Providing better guidelines on intervals between testing2 will facilitate a change in the trend of over-ordering of lab tests.

How can labs provide better guidance; i.e. how often are tests needed? Can we guide testing intervals? What is a meaningful change in a test results?

How can value be added for patients, so that the pathology spend is measured in terms of patient care. Current health funding remains focused on treatment, the cost of hospitalisation dominates the health spend and pathology is often referred to as a “cost centre”.

Dr Rowbotham proposed that the laboratory service be utilised as a risk management strategy for health care outcomes by implementing the following initiatives:

  • Organise and use the lab data
  • Provide incentives to find chronic disease cases within the data
  • Establish constructive testing protocols

These initiatives together contribute to a patient-centric care model. Pathology testing is a valuable component of chronic disease management and healthcare needs to expand on the traditional methods of diagnosis, treatment, compliance monitoring and prognosis to novel and perhaps “disruptive” approaches.

  • Novel – create insight – use the LIS and linked databases to find the patients, based on social and geodemographics. Find insights and change strategies. Look at the data.
  • Disruptive – give patients the information in the right format and keep them well at home.

In summary, the message from the presentation challenged laboratories to meet increasing demands on lab testing in parallel with the increase in patients with chronic disease:

  • Provide better guidance for recommended test ordering
  • Report patient centred results and guided interpretation which enables better management of disease by clinician and patient
  • Utilise data mining – find the trends in data, find and manage the patients, be proactive to help manage the chronic disease epidemic

Written by:Deborah Steele

Deborah Steele is the Health IT Product Manager at Sysmex and oversees the direction of the Sysmex IT product suite. Deborah’s experience includes 9 years as a Medical Laboratory Scientist working in both New Zealand and London, pharmaceutical industry product management, plus 12 years’ in product specialist and marketing roles at Sysmex.

X

You are redirected to a 3rd party website!

Clicking on a social media link implies that you understand you are leaving our site and entering a third-party website. We are not responsible for their content, privacy policies, or terms of use. Please review their terms and privacy policy before proceeding. We do not endorse or control the third-party website and disclaim any liability for damages or consequences.